Citadel Advisors’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,500
| Closed | -$232K | – | 14309 |
|
|
2025
Q4 | $232K | Buy |
+5,500
| New | +$222K | ﹤0.01% | 10712 |
|
|
2025
Q2 | – | Sell |
-2,300
| Closed | -$68.2K | – | 15259 |
|
|
2025
Q1 | $68.2K | Buy |
2,300
+1,700
| +283% | +$64.8K | ﹤0.01% | 11951 |
|
|
2024
Q4 | $23.8K | Sell |
600
-100
| -14% | -$3.79K | ﹤0.01% | 13061 |
|
|
2024
Q3 | $23.8K | Sell |
700
-2,700
| -79% | -$76K | ﹤0.01% | 12641 |
|
|
2024
Q2 | $73.7K | Sell |
3,400
-27,300
| -89% | -$574K | ﹤0.01% | 11311 |
|
|
2024
Q1 | $680K | Buy |
30,700
+400
| +1% | +$9.76K | ﹤0.01% | 7725 |
|
|
2023
Q4 | $834K | Buy |
30,300
+18,700
| +161% | +$451K | ﹤0.01% | 7040 |
|
|
2023
Q3 | $259K | Sell |
11,600
-9,300
| -44% | -$239K | ﹤0.01% | 9433 |
|
|
2023
Q2 | $532K | Buy |
20,900
+2,600
| +14% | +$63K | ﹤0.01% | 7803 |
|
|
2023
Q1 | $408K | Buy |
18,300
+10,100
| +123% | +$244K | ﹤0.01% | 8731 |
|
|
2022
Q4 | $195K | Buy |
+8,200
| New | +$191K | ﹤0.01% | 10185 |
|
|
2022
Q3 | – | Sell |
-42,400
| Closed | -$844K | – | 13670 |
|
|
2022
Q2 | $844K | Buy |
42,400
+18,500
| +77% | +$374K | ﹤0.01% | 7427 |
|
|
2022
Q1 | $659K | Buy |
23,900
+18,600
| +351% | +$532K | ﹤0.01% | 8724 |
|
|
2021
Q4 | $218K | Sell |
5,300
-700
| -12% | -$30.9K | ﹤0.01% | 11669 |
|
|
2021
Q3 | $279K | Sell |
6,000
-7,600
| -56% | -$332K | ﹤0.01% | 11210 |
|
|
2021
Q2 | $544K | Buy |
13,600
+2,700
| +25% | +$115K | ﹤0.01% | 9887 |
|
|
2021
Q1 | $586K | Buy |
+10,900
| New | +$628K | ﹤0.01% | 9337 |
|
|
2019
Q3 | – | Sell |
-13,300
| Closed | -$379K | – | 9788 |
|
|
2019
Q2 | $379K | Sell |
13,300
-700
| -5% | -$17.5K | ﹤0.01% | 7238 |
|
|
2019
Q1 | $350K | Buy |
+14,000
| New | +$267K | ﹤0.01% | 7386 |
|
|
2017
Q3 | – | Sell |
-17,600
| Closed | -$147K | – | 8092 |
|
|
2017
Q2 | $147K | Buy |
17,600
+3,600
| +26% | +$29.4K | ﹤0.01% | 6758 |
|
|
2017
Q1 | $129K | Sell |
14,000
-3,700
| -21% | -$30.3K | ﹤0.01% | 6759 |
|
|
2016
Q4 | $137K | Buy |
+17,700
| New | +$132K | ﹤0.01% | 6551 |
|
|
2016
Q3 | – | Sell |
-10,000
| Closed | -$50K | – | 7821 |
|
|
2016
Q2 | $50K | Sell |
10,000
-9,200
| -48% | -$49.3K | ﹤0.01% | 6408 |
|
|
2016
Q1 | $104K | Buy |
+19,200
| New | +$114K | ﹤0.01% | 6009 |
|
Other funds holding VCYT
VPM
VCM
AIM
Citadel Advisors's VCYT Position: Q1 2026 in Review
Citadel Advisors reduced its Veracyte (VCYT) stake by 4.2% in Q1 2026, selling an estimated $249K and leaving 152,941 shares worth $4.93M. The position accounts for ﹤0.01% of the portfolio, ranked #4362.
Citadel Advisors first reported a position in VCYT in Q4 2015 and has held it in 34 quarters since. The position peaked at $25.5M in Q1 2023. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.
- Citadel Advisors held 152,941 shares of Veracyte worth $4.93M as of Q1 2026.
- Citadel Advisors sold 6,722 Veracyte shares in Q1 2026, an estimated $249K.
- Veracyte made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4362 holding.
- Citadel Advisors first reported a position in Veracyte in Q4 2015 and has held it in 34 quarters since.
- Citadel Advisors's Veracyte position peaked at $25.5M in Q1 2023.
- 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.